Skip to main content

Talk to your doctor about ONUREG (azacitidine)1

for adults who are in first complete remission (with or without recovery of your blood cell counts) after intensive induction chemotherapy and are not able to complete intensive curative therapy.

Bristol Myers Squibb is committed to helping patients gain access to their prescribed BMS medications.

Reference: 1. ONUREG (R) [Prescribing Information], Summit, NJ; Celgene Corporation; 2026



 

Important Safety Information     
Contact Us     Privacy Policy   Your Privacy Choices    Legal Notice

This site is intended for U.S. residents 18 years of age or older.

© 2026 Bristol-Myers Squibb Company. All rights reserved.
ONUREG® is a registered trademark of Celgene Corporation, a Bristol Myers Squibb company.
BMS Access Support® is a registered trademark of Bristol Myers-Squibb Company.
2011-US-2500016 06/26